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Abstract The inhibition of specific transcription regulatory
proteins is a new approach to control gene expression. The
transcriptional activities of DNA-binding proteins can be
inhibited by the use of double-stranded oligonucleotides that
compete for the binding to their specific target sequences in
promoters and enhancers. We used nicked (NDODN-UB) and
circular (CDODN-UB) dumbbell DNA oligonucleotides contain-
ing a NF-UB binding site to analyze the inhibition of the NF-UB-
dependent activation of the human immunodeficiency virus type-1
(HIV-1) enhancer. The dumbbell DNA oligonucleotides are
stable, short segments of double-stranded DNA with closed
nucleotide loops on each end, which confer resistance to
exonucleases. The dumbbell and other oligonucleotides (decoys)
with the NF-UB sequence were found to compete with the native
strand for NF-UB binding. The circular dumbbell and double-
stranded phosphorothioate oligonucleotides competed with the
native strand for binding to the NF-UB binding proteins, while the
nicked NF-UB dumbbell was a less effective competitor. In
Jurkat T-cells, the dumbbell and other oligonucleotides were
tested for their ability to block the activation of the plasmid
HIV-NL4-3 Luc. The CDODN-UB strongly inhibits the specific
transcriptional regulatory proteins, as compared with the
NDODN-UB and the double stranded phosphodiester oligonu-
cleotides. On the other hand, the double stranded phosphoro-
thioate oligonucleotides could also block this activation, but the
effect was non-specific. The circular (CDODN) dumbbell
oligonucleotides may efficiently compete for the binding of
specific transcription factors within cells, thus providing anti-
HIV-1 or other therapeutic effects.
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1. Introduction
The cis-acting regulatory elements that control retroviral
gene expression are thought normally to reside in the long
terminal repeat (LTR) of the virus, particularly within the
U3 region. To regulate their gene expression speci¢cally, the
viruses have evolved their own regulatory gene products.
These viral trans-activators are also dependent upon the cel-
lular factors that interact with the viral proteins and the cis-
acting DNA and RNA regulatory elements to further modu-
late retroviral gene expression. A variety of cellular transcrip-
tion factors contribute to the constitutive expression of retro-
viruses. Among these cellular factors, Sp1 plays an important
role [1], and three Sp1 sites are proximal to the TATA box
from the HIV-1 long terminal repeat (LTR). Of these three
sites, the most upstream site represents the best consensus
sequence and is activated by in vitro transcription [1,2]. Sev-
eral other cis-acting regulatory elements are found near the
TATA box and the transcriptional initiation site. The NF-UB
regulatory element is repeated twice in the HIV-1 enhancer
immediately upstream of the three Sp1 sites. The immune
response gene, NF-UB, has emerged as a unique model for
gene product regulation, which is both adaptable and respon-
sive to cellular activation [3^5]. NF-UB is found in many tis-
sues but its activity is of primary importance within the im-
mune system. As an endpoint for many signal transduction
pathways [4], NF-UB participates in the induction of genes
that encode immunoglobulins, immunoreceptors, cell adhe-
sion molecules, cytokines, immune growth factors and acute
phase proteins. Bound by the inhibitor, IUB, NF-UB is found
in the cytoplasm in an inactive form that, once activated, is
rapidly turned over in response to signals transduced from the
cell surface [6,7]. NF-UB is able to bind in vitro to synthetic
double stranded oligonucleotides, which can be used as se-
quence-speci¢c DNA decoys for the selective sequestering of
transcription factors, rendering then unavailable to bind to
their target DNA [8^10]. As ¢nal result, transcriptional acti-
vation is blocked. Several double-stranded DNAs, such as
phosphodiester oligonucleotide duplexes [11^13], an KL-
anomeric oligonucleotide [14], phosphorothioate oligonucleo-
tide duplexes [15] and dumbbell oligonucleotides [16,17] have
been utilized as decoys for transcription factors. The oligonu-
cleotide duplexes with phosphorothioate backbones exhibit
several advantages over the other forms, including relatively
high nuclease resistance. Double-stranded phosphorothioate
oligonucleotides containing the binding sites for NF-UB or
Oct-1 were shown to inhibit HIV-CAT or Oct-CAT expres-
sion when cotransfected with these reporter vectors in an Ep-
stein-Barr virus-transformed B-cell line [14]. However, the
double-stranded phosphorothioate oligonucleotides have also
shown sequence-independent e¡ects, due to non-sequence spe-
ci¢c protein binding [18]. On the other hand, circular dumb-
bell oligonucleotides have increased nuclease resistance [19,20]
and the uptake [20] into cells, as compared with the nicked
dumbbell- and the linear antisense phosphodiester oligonu-
cleotides. The DNA dumbbell oligonucleotides containing
the binding sites for the liver-enriched transcription factor
hepatocyte nuclear factor 1 (HNF-1) and the X-box of the
DRA promoter were shown to inhibit in vitro transcription
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driven by these DNA-binding proteins in a concentration-spe-
ci¢c manner [16,17].
We are interested in the antisense and decoy abilities of the
circular dumbbell oligonucleotides. In particular, we have an-
alyzed the circular dumbbell oligonucleotides for their se-
quence-speci¢c inhibition of transcription factor activity. As
a model system, we have studied the NF-UB-dependent acti-
vation of the HIV-1 enhancer. Here we show that the circular
dumbbell oligonucleotides containing the NF-UB binding sites
are able to speci¢cally inhibit the NF-UB-dependent activation
of the HIV-1 enhancer in vitro. The circular dumbbell oligo-
nucleotide strongly inhibits the speci¢c transcriptional regula-
tory proteins compared to the nicked dumbbell oligonucleo-
tide and the double stranded phosphodiester oligonucleotides.
However, the double-stranded phosphorothioate oligonucleo-
tides show non-speci¢c binding of transcription factors.
2. Materials and methods
2.1. Oligonucleotide synthesis
The oligonucleotides were synthesized by means of the phosphor-
amidite approach using an Applied Biosystems DNA synthesizer,
Model 392. The 5P-phosphorylated oligonucleotides were synthesized
using a dimethoxytrityl-hexa-ethyloxy-glycol-2-cyanoethyl-N,N-diiso-
propyl phosphoramidite as the phosphorylating agent. The oligonu-
cleotide derivatives were puri¢ed by polyacrylamide gel electrophore-
sis (PAGE) or by reverse phase HPLC chromatography. The
extinction coe⁄cients of the oligonucleotides were determined by cal-
culating the theoretical extinction coe⁄cients as the sum of the nu-
cleosides and multiplying with the experimentally determined enzy-
matic hypochromicity. The 5P-phosphorylated nicked dumbbell
RNA/DNA chimeric oligonucleotide (0.2 A260) was incubated in 10
Wl of 50 mM Tris-HCl, pH 7.5 and 10 mM MgCl2 at 90‡C for 5 min
and then at 15‡C for 2 min. The solution was incubated with 1 Wl of
100 mM dATP, 1 Wl of 25 Wg bovine serum albumin (BSA)/ml and 40
units of T4 DNA ligase at 37‡C for 30 min [21]. The reaction mixture
was extracted with an equal volume of water-saturated chloroform-
phenol (1:1, v/v), and was precipitated with ethanol. The circular
oligonucleotides were puri¢ed by denaturing PAGE (20% polyacryl-
amide containing 7 M urea). The band corresponding to the desired
oligonucleotide was eluted from the gels with water and was precipi-
tated with ethanol. The identity of each of the ligated dumbbells was
veri¢ed by phosphodiesterase protection mapping.
2.2. 3P-End digoxigenin (DIG) labeled DNA
The DNAs (100 pmol) and 1 mM DIG-11-dd-UTP (Roche Diag-
nostics K. K., Germany) in 10 Wl of tailing bu¡er containing 1 M
Tris-HCl, pH 6.6, 1 M potassium cacodylate, 1.25 mg/ml BSA and 25
mM CoCl2, were mixed with 1 Wl of 50 U/Wl terminal transferase and
were kept at 37‡C for 1 h. The reaction was quenched with 1 Wl of a
20 mg/ml glycogen solution and 200 Wl of 0.2 mM EDTA (pH 8.0).
The labeled-DNA was precipitated with 2.5 Wl of 4 M LiCl2 and 75 Wl
of pre-chilled (320‡C) 99% ethanol. The 3P-end digoxigenin (DIG)
labeled DNA was puri¢ed by reversed phase HPLC with a linear
gradient of 5^50% acetonitrile in 0.1 M triethylammonium acetate
(pH 7.0). Non-labeled DNAs were synthesized on the DNA/RNA
synthesizer and were puri¢ed by, 7 M urea denaturing 20% PAGE.
2.3. In vitro competition.
Four femtomol of DIG-labeled duplex and 4.4 ng of the NF-UB
protein (Promega, USA) were incubated in the presence of increasing
concentrations of non-labeled oligonucleotides in 17 Wl of binding
bu¡er, containing 10 mM HEPES, pH 7.9, 50 mM KCI, 1 Wg poly
(I-C) in 10% glycerol and 5 mM dithiothreitol, and the mixture was
incubated at room temperature for 15 min. The NF-UB complexes
with the duplex were separated from the unbound duplex by electro-
phoresis on 6% non-denaturing polyacrylamide gels containing
0.5UTBE (40 mM Tris-borate, pH 8.3 and 2 mM EDTA). The elec-
trophoresis was carried out in 0.5UTBE bu¡er for 2 h at 4‡C. The
relative amounts of the free and bound DNA were determined by a
gel analysis system, LAS-1000 (Fuji Photo Film, Japan).
2.4. Transfections and transient Luc assay
The HIV-NL4-3 Luc vector was generated by substituting nef gene
sequences of the HIV-1 NL4-3 genome with the ¢re£y luciferase gene
and deleting the envelope gene sequences [22]. Aliquots of 3U105
Jurkat cells/ml were plated in 24-well plates the day before transfec-
tion. The plasmid pNL4-3-Luc (3.3 Wg) and the oligonucleotides (22
Wg) were cotransfected with FuGENE-6 (Roche Diagnostics K. K.,
Germany), using the manufacturer’s protocol. After the transfection
and an incubation for 4 h, the cells were incubated for an additional
24 h with PMA (40 nM, Sigma, USA) and PHA (2 Wg/ml, Pharmacia,
USA).
Luciferase assay. To analyze the luciferase expression, the cells were
washed twice with phosphate-bu¡ered saline, and were lysed with 100
Wl of 1Uluciferase lysis bu¡er (Toyo ink, Japan). Ten microliters of
each lysate were subjected to the luciferase assay (Toyo ink Japan),
which was monitored with a Lumat 9507 luminometer (EG and Ber-
thod, Germany) [23].
3. Results and discussion
3.1. Speci¢c binding of the NF-UB to a circular dumbbell
oligonucleotide with the NF-UB target site.
To demonstrate that the phosphodiester and phosphoro-
thioate oligonucleotide duplexes and the dumbbell oligonu-
cleotides interact strongly enough with the NF-UB to act as
decoys, an in vitro competition assay was performed. For this
purpose we chose NF-UB transcription factor, which binds
two NF-UB recognition sequences derived from the long ter-
minal repeat of HIV-1 [4]. We ¢rst performed the electropho-
retic mobility shift assays of human NF-UB towards an NF-
UB site in a double stranded oligonucleotide (ds-UB, Fig. 1).
Constant amounts of the DIG-labeled NF-UB probe oligonu-
Fig. 1. The structure and the sequences of the oligonucleotides used
in this study, as described in the text. The two NF-UB recognition
sequences are underlined in each oligonucleotide. Mutated sequences
are boxed. pt: phosphorothioate group; ds: double-stranded.
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cleotide (DIG-ds-UB) were ¢rst added to increasing amounts
of the competitor oligonucleotides (ds-UB, NDOND-UB and
CDODN-UB). We found that an increase in the non-labeled-
ds-UB decreased the intensity of the retarded band, which
corresponded to the complex formed by the human NF-UB
protein (Fig. 2A, lanes 3^6). A 1000-fold molar excess of the
non-labeled competitor, ds-UB, almost completely competed
for the human NF-UB binding to DIG-ds-UB. When the
nicked dumbbell oligonucleotide, NDOND-UB, was used in
place of ds-UB, as little as a 10-fold molar excess of the
non-labeled competitor, NDOND-UB, completely competed
for the human NF-UB binding to DIG-ds-UB (Fig. 2B). On
the other hand, the addition of a 1000-fold molar excess of the
control oligonucleotide, the NDOND-UB-mut oligonucleotide
containing mutated bases in the human NF-UB site, did not
compete with the DIG-labeled ds-UB for human NF-UB bind-
ing (Fig. 2C). Our data suggest that the dumbbell oligonucleo-
tides may exhibit sequence-dependent e¡ects due to speci¢c
protein binding. Of particular interest, the non-labeled circu-
lar dumbbell oligonucleotide, CDODN-UB, successfully com-
peted with DIG-ds-UB for binding to the human NF-UB bind-
ing protein. Equimolar amounts of CDODN-UB were able to
compete with DIG-ds-UB (Fig. 2D, lane 3). These data indi-
cate that the stability of the double stranded structure in the
non-ligated dumbbell is lower than that of the ligated oligo-
nucleotide and former is probably being displaced to a parti-
ally single stranded form. This result suggests that the circular
dumbbell oligonucleotide (CDODN-UB) has more a⁄nity for
the human NF-UB binding protein than the double-stranded
DNA (ds-UB) and the nicked dumbbell oligonucleotide
(NDODN-UB).
Previous studies by other investigators have shown that the
double-stranded phosphorothioate oligonucleotides compete
for the binding of the speci¢c transcription factor, NF-UB,
and provided anti-viral, immunosuppressive, or other thera-
peutic e¡ects [15]. Furthermore, phosphorothioate oligonu-
cleotides are highly resistant to degradation by nucleases
[24,25], exhibit increased cellular uptake [25,26], and retain
their ability to form sequence-speci¢c duplexes, although
with reduced stability relative to phosphodiester oligonucleo-
tides [27,28]. To con¢rm that the protein binding to the dou-
ble-stranded DNA probe (ds-UBpt) containing phosphoro-
thioate bonds was sequence-speci¢c, an in vitro competition
assay was performed. To our surprise, equimolar amounts of
the non-labeled competitor ds-UBpt completely competed for
human NF-UB binding to DIG-ds-UB (Fig. 2E, lane 3). Con-
trol oligonucleotides were prepared for comparison, such as
the mutated oligonucleotides, ds-UB-mut, ds-UBpt-mut and
CDODN-UB-mut. As shown in Fig. 2E, lanes 7^10, the oli-
gonucleotides (ds-UB-mut and CDODN-UB-mut) containing
mutated bases in the human NF-UB sequences were unable
to compete for the formation of shifted complexes. However,
C
Fig. 2. Competition assay. NF-UB-double stranded oligonucleotide
complexes were formed between labeled DIG-ds-NF-UB (4 fmol)
and the NF-UB protein (4.4 Wg) in the presence of various concen-
trations of unlabeled oligonucleotides. The competitors were present
at 1-, 10-, 100-, and 1000-fold molar excess to the labeled DIG-ds-
NF-UB. Arrows indicate the NF-UB complex (right) and free probe
(left). A: ds-UB competitor. B: NDODN-UB competitor. C:
NDODN-UB-mut competitor. D: CDODN-UB competitor. E: ds-
UBpt, ds-UBpt-mut, ds-UB-mut and CDODN-UB-mut competitors.
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in the case of the double-stranded mutated DNA containing
the phosphorothioate bonds, ds-UBpt-mut, the retarded band
corresponding to the complex formed by the human NF-UB
protein e⁄ciently was absent (Fig. 2E, lanes 4 and 5). On the
other hand, unmodi¢ed double-stranded DNA (ds-UB) was an
about 100-fold less e¡ective competitor than ds-UBpt and ds-
UBpt-mut (Fig. 2A). The results of these competition assays
indicate that protein binding to ds-UBpt correlates with the
presence of phosphorothioates rather than speci¢c sequence.
Consequently, we were unable to assay the phosphorothioate
oligonucleotides, ds-UBpt and ds-UBpt-mut, so they could not
be used to monitor the binding the human NF-UB protein.
Brown et al. [18] have also reported that double stranded
phosphorothioate oligonucleotides may exhibit sequence-inde-
pendent e¡ects due to non-speci¢c protein binding.
3.2. Circular dumbbell oligonucleotides can speci¢cally inhibit
luciferase activity in Jurkat cells
The circular dumbbell oligonucleotides containing the bind-
ing sites for NF-UB were able to interact sequence speci¢cally
with the human NF-UB protein in vitro, while the double
stranded phosphorothioate oligonucleotides showed non-spe-
ci¢c binding to the human NF-UB protein.
In order to evaluate the competition e⁄ciency of the circu-
lar dumbbell oligonucleotides containing the binding sites for
NF-UB, we set up the conditions for cotransfecting Jurkat
cells with plasmids with an envelope-defective HIV-1 genome
expressing the luciferase gene (HIV-NL4-3 Luc) [22]. We then
cotransfected HIV-NL4-3 Luc with oligonucleotides/dumb-
bells containing the binding sites for NF-UB. When 22 Wg of
either CDODN-UB or NDODN-UB were added with the HIV-
NL4-3 Luc, almost 75% and 50% of the luciferase activity was
inhibited, respectively (Fig. 3). It was found that the ligated
dumbbell oligonucleotide (CDODN-UB) was more active than
the unligated oligonucleotide (NDODN-UB) in blocking the
luciferase activity of HIV-NL4-3 Luc [19]. The double
stranded oligonucleotide (ds-UB) was much less active, pre-
sumably due to degradation by exonucleases. In contrast,
under the same conditions, the mutant dumbbells, ds-UB-
mut, CDODN-UB-mut, and NDODN-UB-mut, permitted
maximal luciferase activity (Fig. 3). These results suggest
that the use of dumbbell oligonucleotides results in highly
e⁄cient and speci¢c inhibition of gene expression. On the
other hand, ds-UBpt was more inhibitory than CDODN-UB.
However, the mutant ds-UBpt-mut had inhibitory e¡ects sim-
ilar to those of ds-UBpt. Given the higher nuclease resistance
of the double-stranded phosphorothioate oligonucleotides rel-
ative to the circular dumbbell oligonucleotides, the double-
stranded phosphorothioate oligonucleotides may prove to be
more e¡ective as non-sequence-speci¢c therapeutic agents.
Similarly, it has been shown that inhibition of polymerase
and RNase H activities by the double-stranded phosphoro-
thioate oligonucleotides is directly proportional to the extent
of phosphorothioate modi¢cation [29]. However, it has been
suggested that the non-speci¢c protein binding by phospho-
rothioate-modi¢ed oligonucleotides may impair their ability
to reach the intended therapeutic targets [29^33].
In conclusion, the dumbbell DNA oligonucleotides are sta-
ble, short segments of double-stranded DNA with closed nu-
cleotide loops on each end, which confer resistance to exonu-
cleases. The dumbbells and other oligonucleotides (decoys)
with the NF-UB sequence were found to compete with the
native strand for binding to NF-UB binding proteins. The
circular dumbbell and double-stranded phosphorothioate oli-
gonucleotides competed with the native strand for binding to
the NF-UB binding proteins, while the nicked NF-UB dumb-
bell was a less e¡ective competitor. In Jurkat T-cells, the
dumbbell and other oligonucleotides were tested for their abil-
ity to block the activation of the plasmid HIV-NL4-3 Luc. It
was found that the ligated dumbbell oligonucleotide
(CDODN-UB) was more active than the unligated oligonu-
cleotide (NDODN-UB) and the unmodi¢ed double-stranded
oligonucleotide (ds-UB). On the other hand, the double-
stranded phosphorothioate oligonucleotides (ds-UBpt) could
also block this activation, but the e¡ect correlates with the
presence of phosphorothioates rather than speci¢c sequence.
The circular dumbbell oligonucleotides can e⁄ciently compete
for the binding of speci¢c transcription factors and may pro-
vide anti-HIV-1, or other therapeutic e¡ects.
Acknowledgements: This work was supported in part by a Grant-in-
Aid for High Technology Research and Scienti¢c Research on Prior-
ity Areas, No. 09309011, from the Ministry of Education, Science,
Sports and Culture, Japan.
References
[1] Jones, K.A., Kadonaga, J.T., Luciw, P.A. and Tjian, R. (1986)
Science 232, 755^759.
[2] Nabel, G.J., Rice, S.A., Knipe, D.M. and Baltimore, D. (1988)
Science 239, 1299^1302.
[3] Sen, R. and Baltimore, D. (1986) Cell 46, 705^716.
[4] Baueuerrle, P.A. and Henkel, T. (1994) Annu. Rev. Immunol. 12,
141^179.
[5] Finco, T.S. and Baldwin, A.S. (1995) Immunity 3, 263^272.
[6] Hohmann, H., Remy, R., Scheidereit, C. and van Loon,
A.P.G.M. (1991) Mol. Cell. Biol. 11, 259^266.
[7] Liu, J., Chiles, T.R.S. and Rothatein, T.L. (1991) J. Immunol.
146, 1685^1691.
[8] Bielinska, A., Shivdasani, R.A., Zhang, L.Q. and Nabel, G.J.
(1990) Science 250, 997^1000.
Fig. 3. Inhibition of the NF-UB activity by the oligonucleotides.
Jurkat cells were cotransfected with the plasmid HIV-NL4-3-Luc
(3.3 Wg) and the oligonucleotides (22 Wg) with FuGENE-6. The ac-
tivity of the oligonucleotides is re£ected in their ability to down-
regulate luciferase activity [23].
FEBS 22884 11-11-99
T. Hosoya et al./FEBS Letters 461 (1999) 136^140 139
[9] Holt, T. (1991) Antisense Res. Dev. 1, 365^369.
[10] Clusel, C., Ygarte, E., Enjolras, N., Vasseur, M. and Blumenfeld,
M. (1993) Nucleic Acids Res. 21, 3405^3411.
[11] Scholer, H.R. and Gruss, P. (1984) Cell 36, 403^411.
[12] Cereghini, S., Blumenfeld, M. and Yaniv, M. (1988) Genes Dev.
2, 957^974.
[13] Berkwowitz, L.A., Riabowol, K.T. and Gilman, M.Z. (1989)
Mol. Cell. Biol. 9, 4272^4281.
[14] Tanaka, H., Vickart, P., Bertrand, J.R., Rayner, B., Morvan, R.,
Imbach, J.L., Paulin, D. and Malvy, C. (1994) Nucleic Acids
Res. 22, 3069^3074.
[15] Bielinska, A., Shivdasani, R.A., Zhang, L. and Nabel, G.J.
(1990) Science 250, 997^1000.
[16] Clusel, C., Ugarte, E., Enjolras, N., Vasseur, M. and Blumenfeld,
M. (1993) Nucleic Acids Res. 21, 3405^3411.
[17] Lim, C.S., Jabrane-Ferrat, N., Fontes, J.D., Okamoto, H., Gar-
ovoy, M.R., Peterlin, B.M. and Hunt, C.A. (1997) Nucleic Acids
Res. 25, 575^581.
[18] Brown, D.A., Kang, S.H., Gryaznov, S.M., DeDionisio, L., Hei-
denreich, O., Sullivan, S., Xu, X. and Nerenberg, M.I. (1994)
J. Biol. Chem. 269, 26801^26805.
[19] Chu, B.C.F. and Orgel, L. (1992) Nucleic Acids Res. 20, 5857^
5858.
[20] Abe, T., Takai, K., Nakada, S., Yokota, T. and Takaku, H.
(1998) FEBS Lett. 425, 91^96.
[21] Wang, S. and Kool, E.T. (1994) Nucleic Acids Res. 22, 2326^
2333.
[22] Akkina, R.K., Walton, R.M., Chen, M.L., Li, Q-X., Planelles, V.
and Chen, I.S.Y. (1996) J. Virol. 70, 2581^2585.
[23] An, D.S., Koyanagi, Y., Zhao, J.-Q,, Akkina, R., Bristol, G.,
Yamamoto, N., Zack, J.A. and Chen, I.S.Y. (1997) J. Virol.
71, 1397^1404.
[24] Stein, C.A., Subasinghe, C., Shinozuka, K. and Cohen, J.S.
(1988) Nucleic Acids Res. 16, 3209^3221.
[25] Ho, P.T., Ishiguro, K., Wickstrom, E. and Sartorelli, A.C. (1991)
Antisense Res. Dev. 1, 329^342.
[26] Zhao, Q., Matson, S., Herrera, C.J., Fisher, E., Yu, H. and
Krieg, A.M. (1993) Antisense Res. Dev. 3, 53^66.
[27] Kibler-Herzog, L., Zon, G., Uznanski, B., Whittier, G. and Wil-
son, W.D. (1991) Nucleic Acids Res. 19, 2979^2986.
[28] Vickers, T., Baker, B.F., Cook, P.D., Zounes, M., Buckheit Jr,
R.W., Germany, J. and Ecker, D.J. (1991) Nucleic Acids Res. 19,
3359^3368.
[29] Gao, W.Y., Storm, C., Egan, W. and Cheng, Y.C. (1993) Mol.
Pharmacol. 43, 45^50.
[30] Loke, S.L., Stein, C.A., Zhang, X.H., Mori, K., Nakanishi, M.,
Subasinghe, C., Cohen, J.S. and Neckers, L.M. (1989) Proc.
Natl. Acad. Sci. USA 86, 3474^3478.
[31] Gao, W.Y., Han, F.S., Storm, C., Egan, W. and Cheng, Y.-C.
(1992) Mol. Pharmacol. 41, 223^229.
[32] Stein, C.A. and Cheng, Y.C. (1993) Science 261, 1004^1012.
[33] Hatta, T., Takai, K., Yokoyama, S., Nakashima, H., Yamamoto,
N. and Takaku, H. (1995) Biochem. Biophys. Res. Commun.
211, 1041^1046.
FEBS 22884 11-11-99
T. Hosoya et al./FEBS Letters 461 (1999) 136^140140
